BioNTech美股盘前跌约10%，公司宣布终止二期结直肠癌临床试验。

其他语言标题

• EnglishBioNTech's US-listed shares fell about 10% in pre-market trading as the company announced the termination of its Phase 2 colorectal cancer clinical trial.
• 한국어BioNTech美股盘前下跌约10%，公司宣布终止二期结直肠癌临床试验。